Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
MENLO PARK, Calif., Feb. 26, 2018 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today that Amber Salzman, Ph.D., president and chief executive officer of Adverum, will present at upcoming investor conferences in March.
| Event: | Raymond James 39th Annual Institutional Investors Conference | ||||
| Date: | March 5, 2018 | ||||
| Time: | 9:15 – 9:45 a.m. ET | ||||
| Location: | Orlando, FL | ||||
| Event: | Cowen and Company 38th Annual Health Care Conference | ||||
| Date: | March 12, 2018 | ||||
| Time: | 1:30 – 2:00 p.m. ET | ||||
| Location: | Boston, MA | ||||
| |
A live and replay audio webcast of these presentations will be available from Adverum’s website at http://investors.adverum.com.
About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development. For more information please visit www.adverum.com.
Adverum Contact:
Leone Patterson
Chief Financial Officer
650-665-7222
[email protected]
